Tarsus Pharmaceuticals (TARS) Equity Ratio (2020 - 2025)
Historic Equity Ratio for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to 0.63.
- Tarsus Pharmaceuticals' Equity Ratio fell 67.61% to 0.63 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.63, marking a year-over-year decrease of 67.61%. This contributed to the annual value of 0.6 for FY2024, which is 1972.85% down from last year.
- Tarsus Pharmaceuticals' Equity Ratio amounted to 0.63 in Q3 2025, which was down 67.61% from 0.67 recorded in Q2 2025.
- In the past 5 years, Tarsus Pharmaceuticals' Equity Ratio ranged from a high of 0.95 in Q2 2021 and a low of 0.6 during Q4 2024
- In the last 5 years, Tarsus Pharmaceuticals' Equity Ratio had a median value of 0.8 in 2023 and averaged 0.79.
- As far as peak fluctuations go, Tarsus Pharmaceuticals' Equity Ratio skyrocketed by 58644.8% in 2021, and later plummeted by 2074.23% in 2024.
- Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Equity Ratio stood at 0.93 in 2021, then fell by 9.16% to 0.85 in 2022, then fell by 12.35% to 0.74 in 2023, then fell by 19.73% to 0.6 in 2024, then grew by 5.25% to 0.63 in 2025.
- Its last three reported values are 0.63 in Q3 2025, 0.67 for Q2 2025, and 0.68 during Q1 2025.